Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL460035 | 1.00 | ALDH1A1 (0.37) | ALDH1A1CYP2C19FFAR3CYP1A2CYP2D6 | |
| SCHEMBL4776743 | 0.79 | CYP2C19 (0.42) | ALDH1A1CYP2C19CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL14303404 | 0.77 | ALDH1A1 (0.54) | ALDH1A1CYP2C19SMN1; SMN2HSD17B10CYP3A4 | |
| SCHEMBL438898 | 0.75 | ALDH1A1 (0.37) | ALDH1A1CYP2C19CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL438897 | 0.75 | ALDH1A1 (0.37) | ALDH1A1CYP2C19CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL22217032 | 0.70 | FFAR3 (0.50) | ALDH1A1CYP2C19FFAR3CYP1A2SMN1; SMN2 | |
| SCHEMBL431288 | 0.66 | FFAR3 (0.59) | ALDH1A1CYP2C19FFAR3CYP1A2SMN1; SMN2 | |
| SCHEMBL11799188 | 0.66 | FFAR3 (0.59) | ALDH1A1CYP2C19FFAR3CYP1A2SMN1; SMN2 | |
| SCHEMBL4782482 | 0.65 | CYP2C19 (0.37) | ALDH1A1CYP2C19CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL6845298 | 0.65 | FFAR3 (0.52) | ALDH1A1CYP2C19FFAR3CYP2C9SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | ALDH1A1 272/4885CYP2C19 3016/4885FFAR3 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.